| Title : Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib - Yeo_2017_PLoS.One_12_e0182115 |
| Author(s) : Yeo A , Li L , Warren L , Aponte J , Fraser D , King K , Johansson K , Barnes A , Macphee C , Davies R , Chissoe S , Tarka E , O'Donoghue ML , White HD , Wallentin L , Waterworth D |
| Ref : PLoS ONE , 12 :e0182115 , 2017 |
| Abstract : Yeo_2017_PLoS.One_12_e0182115 |
| ESTHER : Yeo_2017_PLoS.One_12_e0182115 |
| PubMedSearch : Yeo_2017_PLoS.One_12_e0182115 |
| PubMedID: 28753643 |
| Gene_locus related to this paper: human-PLA2G7 |
| Gene_locus related to this paper: human-PLA2G7 |
Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, Macphee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D (2017)
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib
PLoS ONE
12 :e0182115
Yeo A, Li L, Warren L, Aponte J, Fraser D, King K, Johansson K, Barnes A, Macphee C, Davies R, Chissoe S, Tarka E, O'Donoghue ML, White HD, Wallentin L, Waterworth D (2017)
PLoS ONE
12 :e0182115